For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 in 3 will see their cancer return — typically within a year following completion of their initial treatment. Today, the current standard of care following initial chemotherapy is to “watch and wait,” an approach that monitors the patient for signs of relapse.